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Abstract
Background: On January 1, 2005, Medicare began covering a ‘‘Welcome to Medicare’’ visit (WMV) for new
enrollees with fee-for-service (FFS) Medicare (Parts A and B). The new benefit was expected to increase demand
for mammography and Pap tests among women transitioning onto Medicare. This study examined whether
Medicare’s coverage of a WMV influenced the use of mammography and Pap tests among women aged 65 and
66 years with FFS Medicare.
Methods: Medicare Current Beneficiary Survey (MCBS) data from 2001 to 2007 were linked with Medicare
claims. Utilization rates for preventive visits, mammography, and Pap tests were measured among women
entering Medicare. Multivariate logistic regressions were estimated to quantify the effects of the new Medicare
benefit on the use of these screening tests, controlling for patient characteristics.
Results: Regression-adjusted mammography and Pap test rates did not increase after WMV coverage was
introduced. The 2005 reform had nonsignificant trivial effects on the use of both tests, most likely because few of
the women who were eligible for a WMV took advantage of it.
Conclusions: Medicare coverage of a WMV had no impact on mammography screenings or Pap tests among
women who were eligible for the benefit.
Introduction
Effective January 1, 2005, Medicare began covering aone-time initial preventive visit, known as the ‘‘Welcome
to Medicare’’ visit (WMV). This preventive visit was made
available to new beneficiaries within 6 months of beginning
their Part B coverage.1 In addition to measuring height,
weight, and blood pressure, the WMV was to include edu-
cation, counseling, and referrals for other preventive services
already covered under Medicare, including breast and cervi-
cal cancer screening tests.2 It was believed that this initial visit
would allow physicians and patients to spend time empha-
sizing prevention and cancer screening during a visit when
patients were not preoccupied with symptoms or their treat-
ment plans for other health problems. Medicare’s regular cost-
sharing provisions applied to the visit; that is, it was subject to
the Medicare annual Part B deductible and a standard 20%
Medicare copay above that amount.
Despite new screening modalities, mammography remains
the main screening tool for breast cancer in the general pop-
ulation.3 Until recently, Pap smear cervical cytology was the
only screening test available for cervical cancer. Pap smear
tests and mammography screenings were first covered under
Medicare Part B as preventive services for women in 1990 and
1991, respectively (Table 1). In 1998, Medicare waived its Part
B deductible for Pap smears and mammography, but until
2011, a woman was still responsible for her standard Medi-
care copays. As a result of the 2010 Affordable Care Act
(ACA), beginning January 1, 2011, Medicare waived its co-
pays for mammography and Pap smears, thereby eliminating
any out-of-pocket costs associated with these tests. A
screening mammography may be billed to Medicare once a
year, and a screening Pap smear may be billed once every 3
years. More frequent mammography screenings and Pap
smears are covered by Medicare only if a woman is at higher
risk for breast cancer and/or cervical or vaginal cancer.
Nevertheless, although Medicare has provided more gener-
ous coverage for cancer screening over time, the US Pre-
ventive Services Task Force (USPSTF) has further specified its
recommendations by age group, and in 2003, the USPSTF
reinstated its upper age limit of 65 years for cervical cancer
screening (Table 1). Thus, as of 2003, most age-eligible
Medicare beneficiaries were no longer being recommended
for cervical cancer screening under USPSTF guidelines.
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up to age 65
1 test every 3 years 1990
20% copayment;
$100 deductible
January 1, 1991 Mammograms first covered 1991
1 test between ages
35 and 39 years
1992
1 test every 11 months













January 1, 1998 Mammograms 1998
Part B deductible waived;
20% copay still applies
1999
Pap smears 2000
Part B deductible waived;
20% copay still applies





2003 2003—Pap test every
3 years;
up to age 65
2004
January 1, 2005 Welcome to Medicare
first covered
2005
1 visit within 6 months





January 1, 2008 Welcome to Medicare 2008
1 visit within 12 months
of Part B coverage 2009 2009—Mammogram
every 2 years;
ages 50–74
Part B deductible waived;
20% copay still applies
2010
January 1, 2011 Wellness Visit first covered 2011
1 visit every 12 months
No cost to beneficiary
Welcome to Medicare
No cost to beneficiary
Mammograms
No cost to beneficiary
Pap smears
No cost to beneficiary
USPSTF, United States Preventive Services Task Force.
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This article examines the effects of covering a WMV on the
receipt of cancer screening among women who were newly
enrolling in Medicare. Using data from the 2001–2007 Medi-
care Current Beneficiary Survey (MCBS), we evaluate whe-
ther offering coverage of a WMV influenced the receipt of
mammography screenings and Pap tests among women aged
65 and 66 years with fee-for-service (FFS) Medicare.
Background
Prior to 2005, advocacy groups, including the American
Cancer Society (ACS),2 had argued that allowing coverage for
an initial preventive visit under Medicare would improve
cancer screening rates and health outcomes among benefi-
ciaries. The reasoning behind the WMV was to establish a
source of primary care for new beneficiaries who may lack
access to care and to provide a dedicated opportunity to
emphasize health promotion and cancer screening among this
group. Although Medicare had already been covering Pap
tests and mammograms for some time (Table 1), it was be-
lieved that face-to-face visits focused on preventive care and
good health habits were critical to attaining age-appropriate
screening behaviors among older women.
Even though a woman could have obtained—and still
can—screening mammograms without a referral or a pre-
scription from her doctor,4 self-referral for mammography
was the exception rather than the norm. Self-referrals com-
prise only about 6% of all mammograms.5 Most mammo-
grams and Pap tests occur only after a woman receive a
recommendation from a physician to get screened.5–8 In ad-
dition, approximately 80% of women who have not had a
recent mammogram say it is because their physician did not
suggest getting one.9,10 A lack of physician recommendation
was also known to contribute to the underuse of Pap tests
among older women.7,11,12
Physician referrals for cancer screening are much more
likely to be given during office visits focused on preventive
care than during office visits for acute or chronic health
problems.13,14 Thus, there was evidence strongly suggesting
that Medicare coverage for an initial preventive visit might
increase cancer screening rates. We turn now to an empirical
test of whether it actually did.
Materials and Methods
Data sources and sample
Data for this study come from the Medicare Current Ben-
eficiary Survey (MCBS), an annual panel survey sponsored by
the Centers for Medicare and Medicaid Services (CMS). Since
1991, the MCBS has been administered to a nationally repre-
sentative sample of the Medicare population by a face-to-face
interview in three waves, and it covers a host of topics, in-
cluding health status, health insurance coverage and financ-
ing, access to care, knowledge and understanding of
Medicare, and use and effectiveness of new program benefits
and changes. The sampling scheme and methods for data
collection in the MCBS have been described elsewhere in
detail.15 The Institutional Review Board of the University of
North Carolina at Chapel Hill approved all aspects of the
study protocol.
Several prior studies have used the MCBS to examine
cancer screening and use of other preventive services within
the Medicare population.16–20 We used data from the 2001–
2007 MCBS for our analysis, along with the annual outpatient
and inpatient claims data for each respondent. At a benefi-
ciary level, we linked the MCBS Cost and Use modules for
each year to their respective annual Medicare claims and then
pooled the data for years 2001–2007.
Our sample is restricted to female Medicare beneficiaries,
aged 65–68 years, holding FFS Medicare (Parts A and B) rather
than belonging to a Medicare health maintenance organiza-
tion (HMO) plan and were not enrolled in Medicaid during
the survey year. For purposes of analysis, we divide these
women into two groups: a treatment group consisting of
women aged 65 and 66 years and a comparison group con-
sisting of women aged 67 and 68 years. The treatment group is
limited to ages 65 and 66 because the WMV was only covered
during a woman’s first 6 months on Medicare, which would
typically be during the 6 months following her 65th birthday.
Women aged 66 years are included in the treatment group
because some may have had a WMV but delayed their cancer
screenings until they were due for the tests the following year.
The comparison group includes women aged 67 and 68 years
because these women were ineligible for a WMV, but in other
respects, their Medicare coverage was the same. In both
groups, we exclude women enrolled in Medicare HMOs be-
cause Medicare’s coverage of a WMV did not apply to them,
and we exclude women who also had Medicaid because in
most states Medicaid already covered similar visits. We fur-
ther exclude beneficiaries with any history of end-stage renal
disease, breast cancer (for the mammography cohort), and
cervical cancer (for the Pap smear cohort).
Measures of preventive visits and cancer screening
Our first outcome of interest was the percentage of women
who had at least one preventive visit during the survey year.
A binary variable was created from the Part B claims data
using the Health Care Common Procedure Coding System
(HCPCS). In addition to HCPCS codes associated with WMV
claims (G0402 through G0405), we included HCPCS codes
99387 and 99397 for comprehensive preventive medicine
evaluation and management visits for individuals aged ‡ 65.
As providers are generally reluctant to change their billing
practices and some may not have realized initially that the
WMV has its own billing code, we took into consideration the
possibility of coding the WMV as a 993 · 7 procedure. This
approach made our estimated WMV utilization rate an upper-
bound estimate.
For breast cancer screening, our outcome of interest was the
percentage of eligible women who had at least one mammo-
gram during the survey year. The codes used to identify a
mammography screening were 76092, 77057, and G0202. For
cervical cancer, our outcome was the percentage of women
who received at least one Pap test during that year. To identify
Pap smears, we used the following codes: G0123, G0124,
G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001,
and Q0091.
Medicare claims and survey data
We constructed a (0, 1) indicator of whether Medicare
covered a WMV at the time of the survey, which equals 1 for
years 2005–2007 and 0 for years 2001–2004. Another (0, 1)
indicator was constructed to describe whether the respondent
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belongs to the treatment (1) vs. comparison (0) group. The key
parameter of interest is the interaction term between the
WMV flag and treatment/control flag. The MCBS data pro-
vide information on several other variables expected to in-
fluence the receipt of cancer screenings among women.
Individual-level characteristics in each model include annual
household income, educational attainment, whether the wo-
man carries employer-sponsored health insurance in addition
to Medicare, whether she holds a Medigap supplemental
policy, marital status, self-rated overall health status (excel-
lent, very good, good, fair, or poor), history of mental health
problems, prior diagnoses of other nonskin cancers, smoking
status, and race/ethnicity. The MCBS also captured whether
the respondent resided in a metropolitan area and the Census
region. Health Professional Shortage Area (HPSA) designa-
tion was obtained from the Area Resource File (ARF) and
linked to MCBS respondents by ZIP code.21
Statistical analysis
We compared baseline characteristics of our treatment
group, women newly enrolled in Medicare (aged 65–66
years), with those of the comparison group, women aged 67–
68 years, using chi-square tests. We then estimated three dif-
ference-in-differences (DD) models22 to assess the impact of
the WMV coverage on each of our three outcome variables. To
estimate each DD model, the treatment and comparison
groups were pooled, and a multivariate logistic regression
was fit to determine if the introduction of Medicare coverage
for a WMV increased the likelihood of that outcome. In all
models, we controlled for the WMV flag, the treatment group
flag, and the interaction of these two variables, in addition to
other factors that may have influenced the receipt of such
services. The three models describe having received a pre-
ventive visit, a screening mammography, and a Pap smear,
respectively, during the past year. All analyses were con-
ducted using SUDAAN statistical software (version 10) (RTI
International, Research Triangle Park, NC) and included the
complex survey sampling weights that produce nationally
representative results.
Results
After pooling the 7 years in the observation period, a total
of 1577 women newly enrolled in Medicare (aged 65–66 years)
met the sample inclusion criteria (Table 2). The comparison
group included 2126 women aged 67–68 years. Of new en-
rollees who did not report a history of breast cancer, 25%
received a mammography screening during the observed
year vs. 35% in the comparison group. Of new enrollees who
did not report a history of cervical cancer, 11% received a Pap
smear test in the treatment group and 14% in the comparison
group. Only 3.4% of the treatment group had at least one
claim for a preventive visit vs. 5% in the comparison group.
On estimating the models, we found no evidence of an
increase in the likelihood of receiving preventive visits,
mammography, or Pap smears among women after the in-
troduction of coverage of the WMV. We examined regression-
adjusted mean changes by year in the likelihood that a woman
received a mammography screening, relative to the im-
plementation of coverage for a WMV (Fig. 1). For the treat-
ment group, the changes in rates of mammography from year
to year were small (e.g., the largest annual change was + 2.2%
in 2003), and the change over the entire 2001–2007 period was
only + 1.4%. Similarly annual changes in Pap smear rates for
the treatment group were small (largest was - 3.1% in 2007),
and the change over the entire observation period was + 2.6%.
Compared with 2004, Pap smear rates declined by 1.8%, 1.0%,
and 3.2% in 2005, 2006, and 2007, respectively.
In the estimated logistic regressions (Table 3), the first col-
umn reports the odds ratios (ORs) associated with the likeli-
hood of receiving a preventive visit. The interaction term
Table 2. Sample Characteristics, Female Respondents
from Medicare Current Beneficiary Survey










Mammography,a % 25.3 35.2 < 0.01




Survey year ‡ 2005 (WMV
introduction), %
41.6 43.0 0.44
Medicare supplemental coverage, %
Medigap, % 7.3 10.5 < 0.01
Employer-based, % 40.8 40.1 0.59
Census region, %
Northeast 18.6 17.0 0.28
Midwest 22.6 23.2 0.70
South 39.0 39.6 0.74
West 19.8 20.2 0.79
Race/ethnicity, %
White 79.3 80.9 0.13
Black 7.2 6.7 0.53
Hispanic 6.9 7.2 0.62
Married, % 62.0 61.8 0.81
Smoker, % 15.1 13.5 0.19
History of nonskin cancer, % 13.2 14.9 0.06
History of breast cancer, % 5.4 6.1 0.26
History of cervical cancer, % 0.8 0.8 0.87
History of mental health
issues, %
18.1 16.6 0.26
General health status, %
Excellent 22.6 19.6 0.06
Very good 30.2 33.8 0.02
Good 28.8 30.0 0.52
Fair 13.4 12.3 0.31
Poor 4.9 3.5 0.05
Less than high school, % 18.8 17.7 0.37
Household income
< $25,000, %




Residence in HPSA, % 17.5 20.4 0.06
Mammography cohort size 1,485 1,993




Weighted sample size 10,581,445 10,685,374
aAmong mammography cohort only (excludes breast cancer
patients).
bAmong Pap smear cohort only (excludes cervical cancer patients).
HPSA, health professional service area; WMV, ‘‘Welcome to
Medicare’’ visit.
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between WMV coverage and age group is nonsignificant after
adjusting for other covariates. In this model, having a history
of mental problems was significantly associated with higher
likelihood of receiving a preventive visit (OR 1.18), and re-
porting fair or poor health was significantly associated with
lower likelihood of a visit (OR 0.35). Additional control vari-
ables were significant predictors of cancer screening use in the
other two models, including having supplemental insurance
coverage, being married, and being a smoker. However, both
the mammography and Pap smear models yielded nonsig-
nificant effects for the interaction term between WMV cov-
erage and age group.
We also estimated the models a number of other ways to
check the robustness of our findings (data not shown). Our
substantive results remained unchanged. First, we re-
estimated both of the regressions in Table 3 excluding women
FIG. 1. Adjusted change in
the share of new Medicare
enrollees (and compliance
group) receiving mammo-
grams and Pap smears, by
year relative to January 2005
benefit change.
Table 3. Multivariate Logit Models of Variables Associated with Receipt of Preventive Visits and Cancer
Screening Among Female Respondents to Medicare Current Beneficiary Survey Between 2001 and 2007
Preventive visit Mammogram Pap smear
Characteristics OR (95% CI) p value OR (95% CI) p value OR (95% CI) p value
Age 65–66 (vs. 67–68) years 0.58 (0.38-0.87) 0.01 0.58 (0.47-0.71) < 0.01 0.90 (0.69-1.17) 0.43
Survey year ‡ 2005 (WMV available) 0.71 (0.44-1.14) 0.16 0.79 (0.63-0.98) 0.04 0.78 (0.59-1.04) 0.09
(Age 65–66 years) · (year ‡ 2005) 1.62 (0.76-3.44) 0.21 1.34 (0.93-1.95) 0.12 1.23 (0.77-1.97) 0.38
Medigap coverage 1.50 (0.84-2.68) 0.17 2.32 (1.66-3.23) < 0.01 1.79 (1.25-2.56) < 0.01
Employer-based coverage 1.28 (0.85-1.93) 0.24 1.61 (1.29-2.00) < 0.01 1.47 (1.09-1.99) 0.01
Northeast 1.51 (0.61-3.76) 0.37 1.95 (1.33-2.87) < 0.01 1.60 (1.04-2.46) 0.03
Midwest 2.80 (1.22-6.41) 0.02 1.82 (1.30-2.54) < 0.01 1.94 (1.22-3.11) < 0.01
South 1.59 (0.76-3.30) 0.21 1.80 (1.28-2.52) < 0.01 1.86 (1.28-2.69) < 0.01
Black 0.65 (0.28-1.49) 0.31 0.82 (0.55-1.22) 0.33 0.89 (0.53-1.49) 0.66
Hispanic 0.32 (0.08-1.32) 0.12 0.58 (0.36-0.93) 0.02 0.84 (0.42-1.70) 0.64
Married 1.08 (0.71-1.66) 0.71 1.48 (1.19-1.84) < 0.01 1.38 (1.01-1.90) 0.04
Smoker 0.85 (0.51-1.42) 0.53 0.61 (0.44-0.85) < 0.01 0.65 (0.44-0.98) 0.04
History of nonskin cancer 1.18 (0.73-1.93) 0.50 1.20 (0.92-1.55) 0.18 1.57 (1.12-2.19) 0.01
History of mental health issues 1.54 (1.00-2.36) 0.05 1.26 (0.99-1.59) 0.06 1.30 (0.96-1.75) 0.09
Fair/poor health 0.35 (0.17-0.73) < 0.01 0.91 (0.71-1.16) 0.43 0.90 (0.61-1.33) 0.58
Less than high school 0.66 (0.33-1.33) 0.24 0.76 (0.58-1.00) 0.05 0.74 (0.49-1.10) 0.14
Household income < $25,000 0.60 (0.36-1.01) 0.06 0.79 (0.65-0.96) 0.02 1.03 (0.80-1.33) 0.82
Residence in metropolitan area 1.75 (0.91-3.38) 0.09 0.73 (0.57-0.93) 0.01 0.99 (0.71-1.38) 0.94
Residence in HPSA 1.01 (0.54-1.89) 0.98 0.83 (0.63-1.09) 0.17 0.93 (0.69-1.26) 0.65
Cohort size 3,703 3,478 3,665
Weighted sample size 21,266,819 20,036,343 21,091,963
CI, confidence interval; OR, odds ratio.
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aged 66 years, given the possibility that their inclusion in the
sample might have diluted the estimated effect of coverage of
a WMV. Even with this change in the sample, not much
changed. The coefficients on the interaction term remained
nonsignificant in these models. We then reestimated the
models excluding women who had employer-sponsored
health coverage in addition to Medicare, on the possibility
that some of them may have already had coverage for a pre-
ventive visit through their employer plan, in which case
Medicare’s WMV benefit would have been duplicative cov-
erage, not something new. We also considered a Pap smear
model that excluded women who have had a hysterectomy
(and thus do not require testing). The coefficients on the in-
teraction term remained statistically nonsignificant in each of
the alternative models.
Discussion
In 2006, approximately 1300 new enrollees in Medicare
were surveyed as part of the MCBS’s New Enrollee Supple-
ment, a special survey administered in that year. Fewer than
3% of the beneficiaries who were eligible to receive a WMV
said they took advantage of the benefit.23 According to those
individuals surveyed, the main reason for not pursuing a
WMV was that they did not know about the benefit. Of the
respondents, 78% said they would have pursued it had they
known about its availability. Our claims-based rates of pre-
ventive visits are consistent with these findings. Therefore, it
comes as no surprise that the introduction of coverage for a
WMV had no effects on cancer screening rates among women
newly entering Medicare.
Currently, the WMV is reimbursed only once for Medicare
beneficiaries and only during their first year after enrolling in
Medicare Part B. When the program began in 2005, benefi-
ciaries could take advantage of the visit only during their first
6 months in Part B. For some beneficiaries, it may have taken
longer than 6 months to obtain an appointment for a visit.24
Providers may be less inclined to design a visit that provides a
complex set of services described in the regulation if only a
very small percentage of their patients is eligible for it each
year. An important research area to investigate is the behavior
of providers in response to these new benefits. It is possible
that one visit is not enough to adequately address preventive
care, which requires an ongoing relationship between the
patient and provider. With the pressures of today’s primary
care environment, it may be difficult for a clinician to ad-
minister the screening questions and provide the necessary
follow-up counseling in just one visit. It is also possible that
some clinicians find reimbursement for the WMV (approxi-
mately $125)25 inadequate.
A few changes to the WMV benefit were made in 2008,
under the Medicare Improvements for Patients and Providers
Act. Most notably, Medicare began waiving its Part B de-
ductible for the visit, and new enrollees were given 1 year
instead of 6 months from their Medicare enrollment date to
take advantage of the benefit. Beneficiaries were still liable for
their Medicare copay for the visit (i.e., 20% of Medicare’s
approved amount, or approximately $25). The 2010 ACA
eliminated the Medicare copay for this visit, effective January
1, 2011, so beneficiaries now pay nothing when they receive it,
provided their doctors accept Medicare assignment (i.e., the
doctor accepts the amount Medicare approves as payment in
full). Follow-up analysis will be needed to determine if these
changes resulted in increased use.
The ACA also includes several new preventive care bene-
fits for Medicare beneficiaries. Among them is an annual
wellness visit benefit, which is available to beneficiaries of all
ages with FFS Medicare, not just new enrollees. The wellness
visit is meant to be a visit during which the beneficiary and
her physician develop or update a personalized prevention
plan, including a schedule for receiving cancer screenings,
such as a mammography screening and Pap smear. Like the
WMV, the wellness visit will be fully covered, so beneficiaries
pay nothing to receive it provided their doctors accept
assignment.
Conclusions
Our findings in this article raise questions about the po-
tential efficacy of the new wellness visit. Although it is in-
tended to increase the use of preventive care and even though
cost sharing is dropped from the new benefit and it is avail-
able to all FFS Medicare enrollees, our findings raise questions
of whether it will have any effects at all. The reason is that the
new benefit shares several of the characteristics of the WMV.
In 2011, the first year the wellness visit was available, only
1.35 million (approximately 3%) Medicare beneficiaries re-
ceived it.26 The motivation of providers to increase cancer
screening rates among Medicare beneficiaries should be fur-
ther examined.
A limitation of this study is that we were unable to track the
healthcare utilization history of study subjects before their
Medicare enrollment. In addition, screening rates in the MCBS
are reported for the past year only, whereas screening rec-
ommendations for mammography and Pap smear call for
longer time intervals between each test. Some women enter-
ing Medicare may have been screened for cancer before their
enrollment in the program and, based on guideline recom-
mendations, may not have required another screening until
after their WMV eligibility period. Our finding that younger
Medicare beneficiaries were less likely to receive preventive
visits and mammograms relative to their older counterparts
underscores that privately insured women may be getting
these services before aging into Medicare. Further, it is diffi-
cult to accurately capture all preventive visits because pro-
viders may not be properly billing these services. Providers
who did not bill for preventive visits as the primary visit type
prior to 2005 would have been reluctant to bill for the WMV
after it was introduced. Finally, this study examined whether
the availability of a WMV benefit influenced cancer screening
use. Because WMV utilization rates were so low, we were
unable to determine if the lack of effect on screening rates was
caused by the low uptake of these visits or by the ineffec-
tiveness of WMVs when they occurred. Although introduc-
tion of the WMV did not have an impact on overall cancer
screening rates, it may have been valuable for those women
who actually used it. Unfortunately, because so few women in
our sample actually had a WMV, we were unable to formally
test that hypothesis.
In summary, we did not find an increase in cancer screen-
ing rates among women newly enrolled in Medicare after the
introduction of the WMV benefit. These results are consistent
with recent trends in mammography and Pap smear rates in
the general population.27–29 Despite efforts by policymakers
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to improve cancer screening rates within the Medicare pop-
ulation, providers may lack the financial incentives to deliver
preventive services,30 and their reimbursements may not be
aligned with current evidence-based recommendations from
the USPSTF.31 Improving the delivery of screening services to
Medicare beneficiaries may require innovative payment re-
form for these services concordant with USPSTF recommen-
dations.
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